Amyotrophic Lateral Sclerosis Treatment Market – By Treatment Type, By Disease Type, By Route of Administration, By End-use, Global Forecast, 2024 – 2032

Amyotrophic Lateral Sclerosis Treatment Market Size

The global amyotrophic lateral sclerosis treatment market size accounted for USD 713.3 million in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2032. The growth of the market is driven by several key factors, including the rising prevalence of ALS, increased awareness, advancements in therapeutic technologies, and the development of novel treatment options.
 

Additionally, the increasing incidence of ALS is significantly contributing to market growth. For instance, according to the National Institutes of Health (NIH), the number of ALS cases worldwide is projected to rise from 222,801 in 2015 to 376,674 by 2040, underscoring the urgent need for effective interventions and therapies.
 

Advancements in diagnostic technologies have also played a crucial role in the early detection and management of ALS. The introduction of advanced neuroimaging techniques, genetic testing, and biomarker research has enhanced healthcare professionals' ability to identify ALS at earlier stages, enabling timely and personalized treatment approaches, which in turn is driving the growth of the ALS treatment market.
 

Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that affects nerve cells in the brain and spinal cord. Over time, ALS impairs the muscles necessary for movement, speech, eating, and breathing. ALS treatment involves the development, manufacturing, and distribution of therapeutic solutions. The market encompasses a wide range of products, including medications and stem cell therapies, alongside ongoing research into new treatments.
 

Amyotrophic Lateral Sclerosis Treatment Market Trends

The expansion of the market is significantly driven by the development of novel drug therapies. Recent advancements in understanding the genetic and molecular mechanisms underlying ALS have led to the identification of new therapeutic targets. This has fuelled the development of innovative treatments, including gene therapies, antisense oligonucleotides, and neuroprotective agents. Antisense oligonucleotides, which can modulate the expression of specific genes, have shown promise in clinical trials, resulting in accelerated approvals by regulatory agencies. Additionally, neuroprotective agents, which aim to protect nerve cells from damage and slow disease progression, are being explored, further expanding the range of therapeutic options.
 

Amyotrophic Lateral Sclerosis Treatment Market Analysis

Based on treatment type, the market is segmented into medication, stem cell therapy, and other treatment types. The medication segment dominated the market with USD 479.7 million in 2023.
 

• The medication segment of the amyotrophic lateral sclerosis (ALS) treatment market focuses on pharmaceutical interventions aimed at managing symptoms and slowing disease progression.
   
• Medications such as riluzole and edaravone are commonly prescribed to prolong patient survival and reduce oxidative stress on neurons. Riluzole has been shown to modestly extend life expectancy, while edaravone works by mitigating motor neuron damage.
   
• Additionally, ongoing research aims to develop more effective drugs that target the underlying mechanisms of ALS. Market growth in this segment is driven by increasing awareness, government support, and advancements in drug development.
   

Based on disease type, the amyotrophic lateral sclerosis treatment market is divided into sporadic ALS and familial ALS. The sporadic ALS segment accounted for significant market share of 87.3% in 2023.
 

• The sporadic ALS segment of the amyotrophic lateral sclerosis (ALS) treatment market refers to the most common form of ALS, accounting for approximately 90-95% of cases. Unlike familial ALS, sporadic cases have no clear genetic link, making treatment more challenging. According to the Centers for Disease Control and Prevention, sporadic ALS is the most prevalent form of the disease, accounting for 90-95% of ALS cases.
   
• Current therapies focus on symptom management and slowing disease progression through medications such as riluzole and edaravone, as well as supportive care that includes respiratory and nutritional interventions.
   
• Moreover, market growth in this segment is driven by ongoing research, with pharmaceutical companies striving to develop novel treatments to address the complex and unpredictable nature of sporadic ALS.
   

Based on route of administration, the amyotrophic lateral sclerosis treatment market is divided into oral and parenteral. The oral segment is expected to reach 725.2 million by the end of 2032.
 

• The oral segment dominates the ALS treatment market due to its convenience and ease of use for patients. Oral medications, such as riluzole, are widely prescribed to slow disease progression and are preferred by both patients and healthcare providers for long-term management.
   
• This segment's dominance is attributed to better patient compliance, cost-effectiveness, and the non-invasive nature of oral treatments compared to parenteral options like intravenous infusions. As new oral drugs are developed, this segment is expected to maintain its leading position in the ALS treatment market.
   

Based on end-use, the amyotrophic lateral sclerosis treatment market is divided into hospitals, rehabilitation centers, specialty clinics, and other end-users. The hospitals segment dominated the market with USD 329.9 million in 2023.
 

• The hospitals segment plays a crucial role in the ALS treatment market by providing comprehensive care through advanced diagnostics, multidisciplinary treatment teams, and access to the latest therapies. Hospitals offer specialized services, including medication management, respiratory support, and physical therapy, which are essential for ALS patients.
   
• With their capacity to handle complex cases, hospitals remain the primary choice for patients requiring intensive care or experimental treatments, including clinical trials. The segment's growth is driven by technological advancements and an increasing focus on integrated care approaches for ALS management.
   

North America amyotrophic lateral sclerosis treatment market is expected to grow at 5.2% CAGR, to reach USD 515.6 million by 2032.
 

• The U.S. represents a significant portion of the amyotrophic lateral sclerosis (ALS) treatment market in North America, driven by the high prevalence of the disease and a robust healthcare infrastructure.
   
• The U.S. market is characterized by advanced research and development activities, with numerous clinical trials aimed at discovering effective therapies. The FDA's approval of drugs like Riluzole and Edaravone underscores the country’s commitment to expanding treatment options.
   
• Moreover, the presence of leading pharmaceutical companies and collaborations between academic institutions and biotech firms has accelerated the development of innovative treatment modalities.
   

The UK amyotrophic lateral sclerosis treatment market is experiencing robust growth in European market.
 

• The UK is a key player in the ALS treatment market in Europe, reflecting the region's commitment to addressing this debilitating condition. The UK market is supported by a strong healthcare network, including the National Health Service (NHS), which provides comprehensive care for ALS patients.
   
• Furthermore, collaborations between academic institutions, research organizations, and pharmaceutical companies have led to significant advancements in the field, including the exploration of gene therapy and stem cell treatments.
   
• Additionally, patient organizations such as the Motor Neuron Disease Association (MNDA) play a critical role in supporting patients and advocating for increased research funding.
   

The Asia Pacific amyotrophic lateral sclerosis treatment market is expected to witness substantial growth of 6% during the analysis period.
 

• The Asia Pacific region is emerging as a significant market for ALS treatment, driven by increasing awareness and improving healthcare infrastructure.
   
• While the prevalence of ALS in Asia-Pacific is lower compared to Western countries, the market is growing due to rising diagnoses and a greater focus on neurodegenerative diseases. Countries like Japan, China, and South Korea are at the forefront, with Japan being a leader in research and development, particularly in the fields of regenerative medicine and gene therapy.
   
• Furthermore, the Asia-Pacific market is characterized by a diverse healthcare landscape, with varying levels of access to advanced treatments.
   

Amyotrophic Lateral Sclerosis Treatment Market Share

The market is highly competitive, characterized by rapid innovation and technological advancements. Leading pharmaceutical companies hold a significant share of the market, driven by their extensive portfolios of diagnostic tests and advanced treatment options, including a range of medications and emerging therapeutic modalities. Strategic initiatives such as mergers, acquisitions, and collaborations further strengthen the market positions of key players, enabling them to expand their product offerings and access new markets.
 

Amyotrophic Lateral Sclerosis Treatment Market Companies

The company profile section includes both companies that have commercial drugs available in the market as well as those that are onto clinical phase development. Prominent players operating in the amyotrophic lateral sclerosis treatment industry include:

• AB Science
• Biogen Inc.
• Biohaven Pharmaceutical (Pfizer, Inc.)
• BrainStorm Therapeutics, Inc.
• Corestemchemon Inc.
• Eledon Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Ionis Pharmaceuticals, Inc.
• ITF Pharma GmbH
• Mitsubishi Tanabe Pharma Corporation
• Otsuka America Pharmaceutical, Inc.
• Sun Pharmaceutical Industries Ltd.
   

Amyotrophic Lateral Sclerosis Treatment Industry News:

• In May 2022, Eledon Pharmaceuticals, Inc. announced encouraging topline results from its Phase IIa clinical trial evaluating Tegoprubart. Tegoprubart is an investigational drug used in the treatment of amyotrophic lateral sclerosis (ALS). The trial result could significantly impact the company’s portfolio and strengthen its market position in the global market.
   
• In June 2024, Mitsubishi Tanabe Pharma America presented the results from Phase 3b MT-1186-A02 post-marketing study of RADICAVA (edaravone) in amyotrophic lateral sclerosis (ALS). The study confirmed the drug's efficacy in slowing disease progression, reinforcing its role as a critical treatment for ALS patients. These findings are expected to enhance RADICAVA's market penetration and solidify Mitsubishi Tanabe's position in the neurodegenerative disease treatment landscape.
   

The amyotrophic lateral sclerosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Riluzole
  • Edaravone
  • Nuedexta
  • Other medication types
• Stem cell therapy
• Other treatment types

Market, By Disease Type

• Sporadic ALS
• Familial ALS

Market, By Route of Administration

• Oral
• Parenteral

Market, By End-use

• Hospitals
• Rehabilitation centers
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa